Analysis of homologous recombination deficiency in prostate cancer

Analysis of homologous recombination deficiency in prostate cancer

Background. Mutations in homologous recombination repair (HRR) genes (BRCA2, ATM, CHEK2, NBN, etc.) are found in 20–25 % of patients with metastatic prostate cancer (PC) and are an indication for prescription of PARP inhibitors. Sensitivity to these drugs results from homologous recombination defici...

Full description

Saved in:
Bibliographic Details
Main Authors: A. G. Iyevleva, S. N. Aleksakhina, A. P. Sokolenko, E. A. Otradnova, A. S. Nikitina, K. A. Kashko, M. V. Syomina, N. S. Morozova, A. D. Shestakova, E. Sh. Kuligina, E. N. Imyanitov
Format: Article
Language:Russian
Published: Russian Academy of Sciences, Tomsk National Research Medical Center 2025-03-01
Series:Сибирский онкологический журнал
Subjects:
prostate cancer
homologous recombination deficiency
chromosomal instability
hrd score
mutations in homologous recombination genes
parp inhibitors
Online Access:https://www.siboncoj.ru/jour/article/view/3463
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.siboncoj.ru/jour/article/view/3463

Similar Items